Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2007 1
2008 1
2010 1
2013 1
2015 1
2019 1
2021 2
2022 3
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.
Moore KN, Angelergues A, Konecny GE, García Y, Banerjee S, Lorusso D, Lee JY, Moroney JW, Colombo N, Roszak A, Tromp J, Myers T, Lee JW, Beiner M, Cosgrove CM, Cibula D, Martin LP, Sabatier R, Buscema J, Estévez-García P, Coffman L, Nicum S, Duska LR, Pignata S, Gálvez F, Wang Y, Method M, Berkenblit A, Bello Roufai D, Van Gorp T; Gynecologic Oncology Group Partners and the European Network of Gynaecological Oncological Trial Groups. Moore KN, et al. N Engl J Med. 2023 Dec 7;389(23):2162-2174. doi: 10.1056/NEJMoa2309169. N Engl J Med. 2023. PMID: 38055253 Clinical Trial.
A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer.
Holloway RW, Thaker P, Mendivil AA, Ahmad S, Al-Niaimi AN, Barter J, Beck T, Chambers SK, Coleman RL, Crafton SM, Crane E, Ramez E, Ghamande S, Graybill W, Herzog T, Indermaur MD, John VS, Landrum L, Lim PC, Lucci JA, McHale M, Monk BJ, Moore KN, Morris R, O'Malley DM, Reid TJ, Richardson D, Rose PG, Scalici JM, Silasi DA, Tewari K, Wang EW. Holloway RW, et al. Among authors: indermaur md. Int J Gynecol Cancer. 2023 Sep 4;33(9):1458-1463. doi: 10.1136/ijgc-2023-004812. Int J Gynecol Cancer. 2023. PMID: 37666539 Clinical Trial.
Assessing minipig compact jawbone quality at the microscale.
Kochetkova T, Groetsch A, Indermaur M, Peruzzi C, Remund S, Neuenschwander B, Bellon B, Michler J, Zysset P, Schwiedrzik J. Kochetkova T, et al. Among authors: indermaur m. J Mech Behav Biomed Mater. 2022 Oct;134:105405. doi: 10.1016/j.jmbbm.2022.105405. Epub 2022 Aug 1. J Mech Behav Biomed Mater. 2022. PMID: 35947925 Free article.
Teratoma in pregnancy: a case report.
Apostolakis-Kyrus K, Indermaur MD, Prieto J. Apostolakis-Kyrus K, et al. Among authors: indermaur md. J Reprod Med. 2013 Sep-Oct;58(9-10):458-60. J Reprod Med. 2013. PMID: 24050039
Unified validation of a refined second-generation HR-pQCT based homogenized finite element method to predict strength of the distal segments in radius and tibia.
Schenk D, Indermaur M, Simon M, Voumard B, Varga P, Pretterklieber M, Lippuner K, Zysset P. Schenk D, et al. Among authors: indermaur m. J Mech Behav Biomed Mater. 2022 Jul;131:105235. doi: 10.1016/j.jmbbm.2022.105235. Epub 2022 May 2. J Mech Behav Biomed Mater. 2022. PMID: 35588681 Free article.
17 results